Once-daily insulin degludec is another albumin-bound insulin and was shown in double-blind crossover Phase 3 trials to be associated with a reduced rate of overall symptomatic hypoglycaemia during 32 weeks of treatment as compared with once-daily glargine U100 in both type 1 and type 2 diabetes [25, 26]. This evidence concerns the gene INS and Hypoglycemia.